The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder

Young-Hoon Ko, Kyoung Sae Na, Chul Eung Kim, Seung Hyun Kim, Yang Whan Jeon, Jung Seo Yi, Moon-Soo Lee, Shin Gyeom Kim, Hyun-Ghang Jeong, Han Yong Jung

Research output: Contribution to journalArticle

Abstract

Objective Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics. Methods: A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile–including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels–were measured at each follow-up visit. Results: The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles. Conclusion: Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.

Original languageEnglish
Pages (from-to)459-466
Number of pages8
JournalPsychiatry Investigation
Volume11
Issue number4
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Psychotic Disorders
Schizophrenia
Antipsychotic Agents
Triglycerides
Lipids
Waist-Hip Ratio
Metabolome
HDL Lipoproteins
LDL Cholesterol
ziprasidone
Body Mass Index
Therapeutics
Weights and Measures

Keywords

  • Pharmacotherapy
  • Schizophrenia
  • Switching
  • Triglyceride
  • Ziprasidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder. / Ko, Young-Hoon; Na, Kyoung Sae; Kim, Chul Eung; Kim, Seung Hyun; Jeon, Yang Whan; Yi, Jung Seo; Lee, Moon-Soo; Kim, Shin Gyeom; Jeong, Hyun-Ghang; Jung, Han Yong.

In: Psychiatry Investigation, Vol. 11, No. 4, 01.01.2014, p. 459-466.

Research output: Contribution to journalArticle

Ko, Young-Hoon ; Na, Kyoung Sae ; Kim, Chul Eung ; Kim, Seung Hyun ; Jeon, Yang Whan ; Yi, Jung Seo ; Lee, Moon-Soo ; Kim, Shin Gyeom ; Jeong, Hyun-Ghang ; Jung, Han Yong. / The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder. In: Psychiatry Investigation. 2014 ; Vol. 11, No. 4. pp. 459-466.
@article{efffcc76b7ed4871b53f39292d295906,
title = "The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder",
abstract = "Objective Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics. Methods: A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile–including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels–were measured at each follow-up visit. Results: The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles. Conclusion: Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.",
keywords = "Pharmacotherapy, Schizophrenia, Switching, Triglyceride, Ziprasidone",
author = "Young-Hoon Ko and Na, {Kyoung Sae} and Kim, {Chul Eung} and Kim, {Seung Hyun} and Jeon, {Yang Whan} and Yi, {Jung Seo} and Moon-Soo Lee and Kim, {Shin Gyeom} and Hyun-Ghang Jeong and Jung, {Han Yong}",
year = "2014",
month = "1",
day = "1",
doi = "10.4306/pi.2014.11.4.459",
language = "English",
volume = "11",
pages = "459--466",
journal = "Psychiatry Investigation",
issn = "1738-3684",
publisher = "Korean Neuropsychiatric Association",
number = "4",

}

TY - JOUR

T1 - The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder

AU - Ko, Young-Hoon

AU - Na, Kyoung Sae

AU - Kim, Chul Eung

AU - Kim, Seung Hyun

AU - Jeon, Yang Whan

AU - Yi, Jung Seo

AU - Lee, Moon-Soo

AU - Kim, Shin Gyeom

AU - Jeong, Hyun-Ghang

AU - Jung, Han Yong

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics. Methods: A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile–including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels–were measured at each follow-up visit. Results: The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles. Conclusion: Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.

AB - Objective Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics. Methods: A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile–including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels–were measured at each follow-up visit. Results: The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles. Conclusion: Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.

KW - Pharmacotherapy

KW - Schizophrenia

KW - Switching

KW - Triglyceride

KW - Ziprasidone

UR - http://www.scopus.com/inward/record.url?scp=84928167260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928167260&partnerID=8YFLogxK

U2 - 10.4306/pi.2014.11.4.459

DO - 10.4306/pi.2014.11.4.459

M3 - Article

VL - 11

SP - 459

EP - 466

JO - Psychiatry Investigation

JF - Psychiatry Investigation

SN - 1738-3684

IS - 4

ER -